Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes

What Was Tested

The paper reports a study of Insulin Aspart and NPH Insulin (isophane), published as a controlled clinical trial.

Acute hyperglycaemia induces coagulation activation in diabetes patients.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

This was tested in a parallel controlled study in well-controlled patients with type 2 diabetes assigned to bedtime neutral protamine Hagedorn (NPH) insulin (n = 41) or mealtime insulin aspart (n = 37).

Blood samples were collected at 7:40 hours (fasting), 9:30, 11:30, 13:30 and 15:30 hours and analysed for glucose, activated factor VII (FVIIa), D-dimer, prothrombin fragment 1+2 (F1+2), tissue plasminogen activator antigen (t-PA) and plasminogen activator inhibitor activity (PAI).

How the Study Was Run

The design is described as parallel-group.

The Insulin Aspart group and the comparison group ran side by side rather than switching.

They were served standard diabetic meals for breakfast (8:00 hours) and lunch (12:00 hours).

What Was Measured

PubMed files the paper under topics including Biomarkers, Blood Coagulation, Diabetes Mellitus, Type 2, Fibrinolysis, Hypoglycemic Agents, Insulin Aspart and Insulin, Isophane.

What This Means in Plain Language

The paper is a parallel-group study of Insulin Aspart and NPH Insulin (isophane).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, all human trials.